Related Experiment Videos
When drugs don't make it to market
1Faculty of Pharmacy and Charles Perkins Centre, University of Sydney, Charles Perkins Centre D17, NSW Australia 2006 Barbara.mintzes@sydney.edu.au.
BMJ (Clinical Research Ed.)
|June 11, 2015
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Safer use of short-acting beta2-agonists: perceiving and responding to risk-a qualitative study.
The Journal of asthma : official journal of the Association for the Care of Asthma·2026
Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta-analysis.
British journal of clinical pharmacology·2026
Zuranolone: A case study in (regulatory) rush to judgement?
British journal of clinical pharmacology·2026
Selling masculinity - A qualitative analysis of gender representations in social media content about "low T".
Social science & medicine (1982)·2026
Improving the experiences of young adults with the Australian healthcare system.
Australian journal of primary health·2025
Long-Term Follow-Up of Patients Receiving Cell and Gene Therapy Products.
Human gene therapy·2025
Rebalancing innovation, affordability, and access for orphan drugs in the European Union.
The Lancet regional health. Europe·2026
Clinical and Economic Burden of Diseases with Accelerated Approval Therapies: Evidence of Unmet Patient Need.
Therapeutic innovation & regulatory science·2026
The Hidden Burden of Parkinson's Disease in Cambodia: A Call to Action.
Public health challenges·2026